Tom Hallam PhD is CEO of Palisade Bio, a late stage biopharmaceutical company with a focus on gastrointestinal complications from major surgery and getting patients out of the hospital more quickly.
With discoveries about how digestive enzymes can hurt a patient's gastrointestinal tract, their lead asset LB1148 is a liquid that the patient drinks prior to surgery. This drug coats the entire gastrointestinal tract and inhibits digestive enzymes preventing them from attacking underlying tissue.
Palisade is also working on a breakthrough platform technology with the ability for the first time to measure the activity of digestive enzymes when they leak from the gastrointestinal tract into the blood of patients. Since these enzymes belong in the GI tract, when they appear in the blood, they can cause long-term chronic diseases and severe health consequences for patients.